November 10, 2016
BD and JDRF join forces to fight type 1 diabetes
BD has announced a new research collaboration supported by JDRF, the global organization funding…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 10, 2016
Lifeline Scientific leaves AIM due to merger with Shanghai Genext
The merger of Lifeline Scientific with Shanghai Genext Medical Technology and certain of its affiliates dated September 1, 2016, is…
November 10, 2016
Bristol-Myers to develop Nitto's investigational anti-fibrosis drug
Bristol-Myers gets exclusive worldwide rights to develop Nitto’s investigational anti-fibrosis drug
November 10, 2016
The European Patent Office approves Akers Biosciences' Breath Ketone Detector
The European Patent Office has issued a patent covering the Akers Biosciences’ Breath Ketone Detector, a single-use, non-invasive, breath device…
November 10, 2016
Comprehensive loss for Probiodrug in the third quarter of 2016
Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing therapeutic solutions to treat Alzheimer’s disease, has finished the third quarter 2016…
November 10, 2016
Catalyst Pharmaceuticals finishes Q3 2016 with net loss
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating …
November 10, 2016
GENFIT in deal to enhance Medical Knowledge & Landscape of NASH research
GENFIT has signed an agreement for a NASH Registry Project
November 10, 2016
Stada reports 50% net income decrease in Q3 2016 compared to same period last year
Stada reports financial results for Q3 2016…
November 9, 2016
Horizon enters into equipment manufacturing deal with CareDx
Horizon Discovery Group has entered into an Original Equipment Manufacturer (OEM) agreement with CareDx…
November 9, 2016
Bristol-Myers, Infinity Pharmaceuticals join forces to test drug in advanced solid tumors
ristol-Myers Squibb Company and Infinity Pharmaceuticals have announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo …